Redeye comments on BioInvent's second quarter 2026 report. The FDA granted Fast Track designation for BI-1808 in platinum-resistant ovarian cancer on 7 August, while BI-1206's triplet regimen delivered strong non-Hodgkin lymphoma data, with an 83 percent objective response rate and a cleaner tolerability profile than existing options, supporting a partner-led pivotal study targeted for 2027. With runway into the latter part of Q1 2027, the next major catalyst is new funding, through a deal, asset sale or institutional support. The BioInvent share screens as "Attractively Priced".
LÄS MER
